Images List Premium Download Classic

Autoimmune Disease

Autoimmune Disease-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
Ono Pharmaceutical Co., Ltd.
November 09, 2017 - N°20170320949

Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a pd-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in ...
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
Novo Nordisk A/s
November 09, 2017 - N°20170320946

Novel activating receptors of the ig super-family expressed on human myeloid cells, called trem(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of trems, trem-1 and trem-2 are disclosed. Trem-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by ...
Compositions comprising bacterial strains
4d Pharma Research Limited
November 09, 2017 - N°20170319634

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
Autoimmune Disease Patent Pack
Download 255+ patent application PDFs
Autoimmune Disease Patent Applications
Download 255+ Autoimmune Disease-related PDFs
For professional research & prior art discovery
inventor
  • 255+ full patent PDF documents of Autoimmune Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
Gilead Sciences, Inc.
October 26, 2017 - N°20170306050

The present disclosure provides compositions and methods of use comprising a matrix metalloproteinase-9 (mmp9) binding protein, alone or in combination with one or more additional therapeutic agents for the treatment or prevention of diseases and conditions.
Methods of treating autoimmune disease using a domain antibody directed against cd40l
Bristol-myers Squibb Company
October 26, 2017 - N°20170306034

Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (itp), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose ...
Anti-cd100 antibodies and methods for using the same
Vaccinex, Inc.
October 26, 2017 - N°20170306017

Compositions and methods are provided for treating diseases associated with cd100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-cd100 monoclonal antibodies have been developed to neutralize cd100.
Autoimmune Disease Patent Pack
Download 255+ patent application PDFs
Autoimmune Disease Patent Applications
Download 255+ Autoimmune Disease-related PDFs
For professional research & prior art discovery
inventor
  • 255+ full patent PDF documents of Autoimmune Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Crystalline forms of a bruton's tyrosine kinase inhibitor
Pharmacyclics Llc
October 26, 2017 - N°20170305919

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other ...
Artificial antigen-presenting cells and methods for producing and using the same
Indiana University Research And Technology Corporation
October 26, 2017 - N°20170304462

Described herein are biomimetic janus particles useful as artificial antigen presenting cells capable of activating t cells in vitro. “bull's eye” ligand patterns mimicking either the native or reverse organization of the t cell immunological synapse are provided on the surface of nano- or micro-sized particles. Methods for activating t cells in vitro using biomimetic janus ...
Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
October 26, 2017 - N°20170304441

Highly effective combinations of a compound of formula a (a pi3kδ selective inhibitor) and anti-cd20 antibodies are provided herein for the treatment and amelioration of pi3kδ and/or cd20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination ...
Novel epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection
Rappaport Family Institute For Research In The Medical Sciences
October 26, 2017 - N°20170304436

The present invention relates to a peptide comprising an epitope within the macrophage scavenger receptor b-i, a method of using the same, a nucleic acid encoding the same and an antibody that binds to the epitope.
Metallic gold cluster molecules as therapeutic agents for arthritic animals
Rappaport Family Institute For Research In The Medical Sciences
October 26, 2017 - N°20170304408

A therapeutic method for attenuating symptoms of inflammation and autoimmune diseases. This method includes preparing and administering to animals intraperitoneally or orally a metallic gold cluster complex preparation.
Methods for increasing the selective efficacy of gene therapy using car peptide and heparan sulfate ...
Vascular Biosciences
October 26, 2017 - N°20170304389

Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune ...
Substituted bicyclic compounds
Vascular Biosciences
October 26, 2017 - N°20170304332

And/or a salt thereof, wherein r1 is —oh or —op(o)(oh)2, and x1, x2, x3, r2, r2a, ra, rb, and rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or ...
Autoimmune Disease Patent Pack
Download 255+ patent application PDFs
Autoimmune Disease Patent Applications
Download 255+ Autoimmune Disease-related PDFs
For professional research & prior art discovery
inventor
  • 255+ full patent PDF documents of Autoimmune Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application ...
Vascular Biosciences
October 19, 2017 - N°20170298322

The invention provides methods for the ex-vivo expansion of cd4+cd25+ tregs. The invention provides a method for producing ex vivo expanded tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens. Additionally, the ex vivo expanded tregs may provide treatment for inflammatory/autoimmune diseases.
Treatment of il-17 mediated disease by blocking sefir-sefir interactions
Vascular Biosciences
October 19, 2017 - N°20170298095

A method of treating an il-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the sefir domain of il-17r to the sefir domain of act1. In particular, it has been determined that the αc helix region of the sefir ...
Modulators of ror-gamma receptors, composition and use thereof
Vascular Biosciences
October 19, 2017 - N°20170298090

The present invention provides novel methods to treat disease by modulating retinoid-related orphan receptor gamma (ror-gamma) in vitro and in vivo with ursolic acid analogs, and compositions thereof. The methods and compounds disclosed herein are useful for inhibiting the differentiation of a population of t cells, or treating a disease related to th17 cell responses in a subject. Examples of ...
Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
Vascular Biosciences
October 19, 2017 - N°20170298022

Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as h4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
Conjugates of cell binding molecules with cytotoxic agents
Vascular Biosciences
October 19, 2017 - N°20170296663

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.
Cell populations having immunoregulatory activity, method for isolation and uses
Vascular Biosciences
October 19, 2017 - N°20170296593

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (ifn-γ) by expressing indolamine-2,3-dioxygenase (ido) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases ...
Cell populations having immunoregulatory activity, method for isolation and uses
Vascular Biosciences
October 19, 2017 - N°20170296592

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (ifn-γ) by expressing indolamine-2,3-dioxygenase (ido) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases ...
Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
University Of Connecticut
October 12, 2017 - N°20170290864

The disclosure provided herein relates generally to mesenchymal-like stem cells “hes-t-misc” or “t-msc” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hes-t-msc or t-msc, t-msc ...
Loading